Our study retrospectively compared ER, PR, and HER2 receptor profiles in biopsies of primary breast cancer and corresponding metastatic lesions in a large study population to assess individual changes throughout tumor progression and location-specific discordance rates. The gene discussed is ESR1; the disease is breast cancer.